Immune evasion in cancer: Mechanistic basis and therapeutic strategies

Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013

Becker, 2013, Immune-suppressive properties of the tumor microenvironment, Cancer Immunol Immunother, 62, 1137, 10.1007/s00262-013-1434-6

Zamarron, 2011, Dual roles of immune cells and their factors in cancer development and progression, Int J Biol Sci, 7, 651, 10.7150/ijbs.7.651

Blackwill, 2002, Inflammation and cancer: back to Virchow?, Lancet, 357, 539, 10.1016/S0140-6736(00)04046-0

Rakoff-Nahoum, 2007, Why cancer and inflammation, Yale J Biol Med, 79, 123

Grivennikov, 2010, Immunity, inflammation, and cancer, Cell, 140, 883, 10.1016/j.cell.2010.01.025

Karin, 2006, Nuclear factor-kappaB in cancer development and progression, Nature, 441, 431, 10.1038/nature04870

Karin, 2006, Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer, Cell, 124, 823, 10.1016/j.cell.2006.02.016

Park, 2010, Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression, Cell, 140, 197, 10.1016/j.cell.2009.12.052

de Martel, 2009, Infections and cancer: established associations and new hypotheses, Crit Rev Oncol Hematol, 70, 183, 10.1016/j.critrevonc.2008.07.021

Coussens, 2002, Inflammation and cancer, Nature, 420, 860, 10.1038/nature01322

Coussens, 2001, Inflammatory cells and cancer: think different!, J Exp Med, 193, F23, 10.1084/jem.193.6.F23

Dunn, 2002, Cancer immunoediting: from immunosurveillance to tumor escape, Nat Immunol, 3, 991, 10.1038/ni1102-991

Dunn, 2004, The three Es of cancer immunoediting, Annu Rev Immunol, 22, 329, 10.1146/annurev.immunol.22.012703.104803

Sawnn, 2007, Immune surveillance of tumors, J Clin Investig, 117, 1137, 10.1172/JCI31405

Shay, 2004, Hallmarks of senescence in carcinogenesis and cancer therapy, Oncogene, 23, 2919, 10.1038/sj.onc.1207518

Jacobs, 2012, Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?, Lancet Oncol, 13, e32, 10.1016/S1470-2045(11)70155-3

Yokokawa, 2008, Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer, Clin Cancer Res, 14, 1032, 10.1158/1078-0432.CCR-07-2056

Gasparoto, 2010, Patients with oral squamous cell carcinoma are characterized by increased frequency of suppressive regulatory T cells in the blood and tumor microenvironment, Cancer Immunol Immunother, 59, 819, 10.1007/s00262-009-0803-7

Curiel, 2004, Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival, Nat Med, 10, 942, 10.1038/nm1093

Lee, 2005, Recruitment of Foxp3+ T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor, J Exp Med, 201, 1037, 10.1084/jem.20041709

Zou, 2006, Regulatory T cells, tumour immunity and immunotherapy, Nat Rev Immunol, 6, 295, 10.1038/nri1806

Murdoch, 2008, The role of myeloid cells in the promotion of tumour angiogenesis, Nat Rev Cancer, 8, 618, 10.1038/nrc2444

Shozaei, 2008, Role of myeloid cells in tumor angiogenesis and growth, Trends Cell Biol, 18, 372, 10.1016/j.tcb.2008.06.003

Ostrand-Rosenberg, 2012, Regulating the suppressors: apoptosis and inflammation govern the survival of tumor-induced myeloid-derived suppressor cells (MDSC), Cancer Immunol Immunother, 61, 1319, 10.1007/s00262-012-1269-6

Seung, 1995, Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection, Proc Natl Acad Sci USA, 92, 6254, 10.1073/pnas.92.14.6254

Umansky, 2012, Overcoming immunosuppression in the melanoma microenvironment induced by chronic inflammation, Cancer Immunol Immunother, 61, 275, 10.1007/s00262-011-1164-6

Mantovani, 2010, Macrophages, innate immunity and cancer: balance, tolerance, and diversity, Curr Opin Immunol, 22, 231, 10.1016/j.coi.2010.01.009

van Kempen, 2003, The tumor microenvironment: a critical determinant of neoplastic evolution, Eur J Cell Biol, 82, 539, 10.1078/0171-9335-00346

Sica, 2008, Macrophage polarization in tumour progression, Semin Cancer Biol, 18, 349, 10.1016/j.semcancer.2008.03.004

Munn, 2002, Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase, Science, 297, 1867, 10.1126/science.1073514

Garrido, 1997, Implications for immunosurveillance of altered HLA class I phenotypes in human tumours, Immunol Today, 18, 89, 10.1016/S0167-5699(96)10075-X

Hicklin, 1999, HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story, Mol Med Today, 5, 178, 10.1016/S1357-4310(99)01451-3

Johnsen, 1999, Deficiency of transporter for antigen presentation (TAP) in tumor cells allows evasion of immune surveillance and increases tumorigenesis, J Immunol, 163, 4224, 10.4049/jimmunol.163.8.4224

Restifo, 1993, Identification of human cancers deficient in antigen processing, J Exp Med, 177, 265, 10.1084/jem.177.2.265

Rotem-Yehudar, 1996, LMP-associated proteolytic activities and TAP-dependent peptide transport for class 1 MHC molecules are suppressed in cell lines transformed by the highly oncogenic adenovirus 12, J Exp Med, 183, 499, 10.1084/jem.183.2.499

Seliger, 1997, TAP off–tumors on, Immunol Today, 18, 292

Maeurer, 1996, Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen, J Clin Investig, 98, 1633, 10.1172/JCI118958

Pasche, 2001, Role of transforming growth factor beta in cancer, J Cell Physiol, 186, 153, 10.1002/1097-4652(200002)186:2<153::AID-JCP1016>3.0.CO;2-J

Lind, 2004, Tumor necrosis factor receptor 1-mediated signaling is required for skin cancer development induced by NF-kappaB inhibition, Proc Natl Acad Sci USA, 101, 4972, 10.1073/pnas.0307106101

Lin, 2002, The macrophage growth factor CSF-1 in mammary gland development and tumor progression, J Mammary Gland Biol Neoplasia, 7, 147, 10.1023/A:1020399802795

Klein, 1995, IL6 and IL6 receptor expression in Burkitt's lymphoma and lymphoblastoid cell lines: promotion of IL6 receptor expression by EBV, Hematol Oncol, 13, 121, 10.1002/hon.2900130302

Matsuda, 1994, Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression, J Exp Med, 180, 2371, 10.1084/jem.180.6.2371

Sotomayer, 1991, Role of tumor-derived cytokines on the immune system of mice bearing a mammary adenocarcinoma. II. Downregulation of macrophage-mediated cytotoxicity by tumor-derived granulocyte-macrophage colony-stimulating factor, J Immunol, 147, 2816, 10.4049/jimmunol.147.8.2816

Gabrilovich, 1996, Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells, Nat Med, 2, 1096, 10.1038/nm1096-1096

Gabrilovic, 2004, Mechanisms and functional significance of tumor induced dendritic-cell defects, Nat Rev Immunol, 4, 941, 10.1038/nri1498

McKallip, 1999, Tumor gangliosides inhibit the tumor-specific immune response, J Immunol, 163, 3718, 10.4049/jimmunol.163.7.3718

Nakashima, 1999, Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1, Nat Med, 5, 938, 10.1038/11383

Nakabayashi, 2007, Clinic-pathological significance of RCAS1 expression in gliomas: a potential mechanism of tumor immune escape, Cancer Lett, 246, 182, 10.1016/j.canlet.2006.02.021

Sonoda, 2008, The biological role of unique molecule RCAS1: a bioactive marker that induces connective tissue remodeling and lymphocyte apotosis, Front Biosci, 13, 1106, 10.2741/2748

Birkle, 2003, Role of tumor-associated ganglisodes in cancer progression, Biochemie, 85, 455, 10.1016/S0300-9084(03)00006-3

Muller, 2005, Marrying immunotherapy with chemotherapy: why say IDO?, Cancer Res, 65, 8065, 10.1158/0008-5472.CAN-05-2213

Mills, 1992, Macrophage arginine metabolism and the inhibition or stimulation of cancer, J Immunol, 149, 2709, 10.4049/jimmunol.149.8.2709

Boutard, 1995, Transforming growth factor-beta stimulates arginase activity in macrophages. Implications for the regulation of macrophage cytotoxicity, J Immunol, 155, 2077, 10.4049/jimmunol.155.4.2077

Xia, 2012, Reduced cell proliferation by IKK2 depletion in a mouse lung-cancer model, Nat Cell Biol, 10.1038/ncb2428

Prenderghast, 2008, Immune escape as a fundamental trait of cancer: focus on IDO, Oncogene, 27, 3889, 10.1038/onc.2008.35

Munder, 2009, Arginase: an emerging key player in the mammalian immune system, Br J Pharmacol, 158, 10.1111/j.1476-5381.2009.00291.x

Kim, 2006, NF-κB and IKK as therapeutic targets in cancer, Cell Death Differ, 13, 738, 10.1038/sj.cdd.4401877

Staveley-O’Carroll, 1998, Induction of antigen-specific T cell anergy: an early event in the course of tumor progression, Proc Natl Acad Sci USA, 95, 1179, 10.1073/pnas.95.3.1178

Maeda, 1996, TGF-beta contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice, J Immunol, 156, 73, 10.4049/jimmunol.156.1.73

Driessens, 2009, Costimulatory and inhibitory receptors in anti-tumor immunity, Immunol Rev, 229, 126, 10.1111/j.1600-065X.2009.00771.x

Topalian, 2012, Targeting PD-1/B7-H1 (PD-L1) pathway to activate antitumor immunity, Curr Opin Immunol, 24, 207, 10.1016/j.coi.2011.12.009

French, 2002, Defective death receptor signaling as a cause of tumor immune escape, Semin Cancer Biol, 12, 51, 10.1006/scbi.2001.0405

Slavin-Chiorini, 2004, Amplification of the lytic potential of effector/memory CD8+ cells by vector-based enhancement of ICAM-1(CD54) in target cells: implications for intrtumoral vaccine therapy, Cancer Gene Ther, 11, 665, 10.1038/sj.cgt.7700741

Chouaib, 2009, Tumor resistance to specific lysis: a major hurdle for successful immunotherapy of cancer, Clin Immunol, 130, 34, 10.1016/j.clim.2008.08.020

Bogen, 1996, Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma, Eur J Immunol, 26, 2671, 10.1002/eji.1830261119

Lauritzsen, 1998, Clonal deletion of thymocytes as a tumor escape mechanism, Int J Cancer, 78, 216, 10.1002/(SICI)1097-0215(19981005)78:2<216::AID-IJC16>3.0.CO;2-8

Marusky, 2010, Tumor heterogeneity: causes and consequences, Biochim Biophys Acta, 1805, 105

Miller, 1982, Intratumor immunologic heterogeneity, Cancer Metastasis Rev, 1, 319, 10.1007/BF00124215

Campbell, 2007, Breast tumor heterogeneity: cancer stem cells or clonal evolution?, Cell Cycle, 6, 2322, 10.4161/cc.6.19.4914

Dick, 2008, Stem cell concepts renew cancer research, Blood, 112, 4793, 10.1182/blood-2008-08-077941

Fiddler, 1982, Biological diversity in metastatic neoplasms: origins and implications, Science, 217, 998, 10.1126/science.7112116

Heppner, 1984, Tumor heterogeneity, Cancer Res, 44, 2259

Nicolson, 1984, Generation of phenotypic diversity and progression in metastatic tumor cells, Cancer Metastasis Rev, 3, 25, 10.1007/BF00047691

Merlo, 2006, Cancer as an evolutionary and ecological process, Nat Rev Cancer, 6, 924, 10.1038/nrc2013

Ardiani, 2014, Vaccine-mediated immunotherapy directed against a transcription factor driving the metastatic process, Cancer Res, 74, 1945, 10.1158/0008-5472.CAN-13-2045

Butler, 1975, Quantitation of cell shedding into efferent blood of mammary adenocarcinoma, Cancer Res, 35, 512

Tarin, 1984, Mechanisms of human tumor metastasis studied in patients with peritoneovenous shunts, Cancer Res, 44, 3584

Chambers, 2001, Critical steps in hematogenous metastasis: an overview, Surg Oncol Clin N Am, 10, 243, 10.1016/S1055-3207(18)30063-2

Fiddler, 1999, Critical determinants of cancer metastasis: rationale for therapy, Cancer Chemother Pharmacol, 43, S3, 10.1007/s002800051091

Folkman, 1992, The role of angiogenesis in tumor growth, Semin Cancer Biol, 3, 65

Woodhouse, 1997, General mechanisms of metastasis, Cancer, 80, 1529, 10.1002/(SICI)1097-0142(19971015)80:8+<1529::AID-CNCR2>3.0.CO;2-F

Hunter, 2008, Mechanisms of metastasis, Breast Cancer Res, 10, 10.1186/bcr1988

Nowell, 1976, The clonal evolution of tumor cell populations, Science, 194, 23, 10.1126/science.959840

Fidler, 1977, Metastasis results from preexisting variant cells within a malignant tumor, Science, 197, 893, 10.1126/science.887927

Kang, 2003, A multigenic program mediating breast cancer metastasis to bone, Cancer Cell, 3, 537, 10.1016/S1535-6108(03)00132-6

Minn, 2005, Genes that mediate breast cancer metastasis to lung, Nature, 436, 518, 10.1038/nature03799

Minn, 2005, Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors, J Clin Investig, 115, 44, 10.1172/JCI22320

Mundy, 1997, Mechanisms of bone metastasis, Cancer, 80, 1546, 10.1002/(SICI)1097-0142(19971015)80:8+<1546::AID-CNCR4>3.0.CO;2-I

Cooke, 2012, Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway, Cancer Cell, 21, 66, 10.1016/j.ccr.2011.11.024

Branco-Price, 2012, Endothelial cell HIF-1α and HIF-2α differentially regulate metastatic success, Cancer Cell, 21, 52, 10.1016/j.ccr.2011.11.017

Kashiwagi, 2005, NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissue-engineered blood vessels, J Clin Investig, 115, 1816, 10.1172/JCI24015

Erler, 2009, Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche, Cancer Cell, 15, 35, 10.1016/j.ccr.2008.11.012

Sceneay, 2012, Primary tumor hypoxia recruits CD11b+/Ly6Cmed/Ly6G+ immune suppressor cells and compromises NK cell cytotoxicity in the premetastatic niche, Cancer Res, 72, 3906, 10.1158/0008-5472.CAN-11-3873

Bidwell, 2012, Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape, Nat Med, 18

Mackall, 2000, T-cell immunodeficiency following cytotoxic antineoplastic therapy: a review, Stem Cells, 18, 10, 10.1634/stemcells.18-1-10

Noonan, 1977, Cell-mediated immunity and serum blocking factors in cancer patients during chemotherapy and immunotherapy, Cancer Res, 37, 2473

Galluzzi, 2012, The secret ally: immunostimulation by anticancer drugs, Nat Rev Drug Discov, 11, 215, 10.1038/nrd3626

Loi, 2013, CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer, Proc Natl Acad Sci USA, 110, 11091, 10.1073/pnas.1222251110

Garnett, 2008, Combination of docetaxel and recombinant vaccine enhances T-cell responses and anti-tumor activity; effects of docetaxel on immune enhancement, Clin Cancer Rev, 14, 3536, 10.1158/1078-0432.CCR-07-4025

Hodge, 2013, Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death, Int J Cancer, 133, 624, 10.1002/ijc.28070

Uzawa, 1994, Radiosensitivity of CD45RO+ memory and CD45RO+ naïve T cells in culture, Radiat Res, 137, 25, 10.2307/3578787

Ferguson, 1981, The in vitro assessment of the immunesuppressive effect of fractionated total lymphoid irradiation in renal allotransplantation, Transplant Proc, 13, 1673

Lander, 1997, Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress, J Biol Chem, 272, 17810, 10.1074/jbc.272.28.17810

Kasid, 1996, Activation of Raf by ionizing radiation, Nature, 382, 813, 10.1038/382813a0

Ifeadi, 2012, Sub-lethal irradiation of colorectal tumor cells imparts enhanced and sustained susceptibility to multiple death receptor signialing pathways, PLoS ONE, 7, e31762, 10.1371/journal.pone.0031762

Matsumura, 2010, Up-regulation of the proinflammatory chemokine CXCL16 is a common response of tumors cells to ionization radiation, Radiat Res, 173, 418, 10.1667/RR1860.1

Garnett, 2004, Sub-lethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes, Cancer Res, 64, 7985, 10.1158/0008-5472.CAN-04-1525

Kumari, 2013, Turning T cells on: epigenetically enhanced effector T-cell activity following tumor cells irradiation, J Immunother Cancer, 1, 17, 10.1186/2051-1426-1-17

Bernstein, 2014, radiation-induced modulation of costimulatory and coinhibitory T-cell signaling molecules on human prostate carcinoma cells promotes productive anti-tumor immune interactions, Cancer Biother Radiopharm, 29, 153, 10.1089/cbr.2013.1578

Chakraborty, 2004, External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing, Cancer Res, 64, 4328, 10.1158/0008-5472.CAN-04-0073

McBride, 2004, A sense of danger from radiation, Radiat Res, 162, 1, 10.1667/RR3196

Ishihara, 1995, Immediate-early, transient induction of the interleukin-1 beta gene in mouse spleen macrophages by ionizing radiation, J Radiat Res, 36, 112, 10.1269/jrr.36.112

Ehlers, 1973, Abscopal effect of radiation in papillary adenocarcinoma, Br J Radiol, 46, 220, 10.1259/0007-1285-46-543-220

Demaria, 2004, Inozation radiation of distinct unrelated tumors (abscopal effect) is immune mediated, Int J Radiat Oncol Biol Phys, 58, 862, 10.1016/j.ijrobp.2003.09.012

Durante, 2013, Immunologically augmented cancer treatment using modern radiotherapy, Trends Mol Med, 00096

Sylla, 2005, Immunological advantages of advanced laparoscopy, Surg Clin N Am, 85, 1, 10.1016/j.suc.2004.09.005

Gabay, 1999, Acute-phase proteins and other systemic responses to inflammation, N Engl J Med, 340, 448, 10.1056/NEJM199902113400607

Lennard, 1985, The influence of surgical operations on components of the human immune system, Br J Surg, 72, 771, 10.1002/bjs.1800721002

Whelan, 2003, Postoperative cell mediated immune response is better preserved after laparoscopic vs open colorectal resection in humans, Surg Endosc, 17, 972, 10.1007/s00464-001-8263-y

Zhang, 2007, Induction of post-surgical immunity and T-cell memory by a poorly immunogenic tumor, Cancer Res, 67, 6468, 10.1158/0008-5472.CAN-07-1264

Belanich, 1996, Intracellular localization and intercellular heterogeneity of the human DNA repair protein O(6)-methylguanine-DNA methyltransferase, Cancer Chemother Pharmacol, 37, 547, 10.1007/s002800050427

Hotta, 1994, O6-alkylguanine-DNA alkyltransferase activity of human malignant glioma and its clinical implications, J Neurooncol, 21, 135, 10.1007/BF01052897

Sleeman, 2010, Cancer metastasis as a therapeutic target, Eur J Cancer, 46, 1177, 10.1016/j.ejca.2010.02.039

Melief, 2002, Strategies for immunotherapy of cancer, Adv Immunol, 75, 235, 10.1016/S0065-2776(00)75006-1

Itok, 2006, Personalized peptide vaccines: a new therapeutic modality for cancer, Cancer Sci, 97, 970, 10.1111/j.1349-7006.2006.00272.x

Gilboa, 2007, DC-based cancer vaccines, J Clin Investig, 117, 1195, 10.1172/JCI31205

Hodge, 2009, Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and anti-tumor activity in a diversified prime and boost vaccine regimen, Vaccine, 27, 4475, 10.1016/j.vaccine.2009.05.017

Scholm, 2014, Therapeutic cancer vaccines, Adv Cancer Res, 121, 67, 10.1016/B978-0-12-800249-0.00002-0

June, 2007, Adoptive T cell therapy for cancer in the clinic, J Clin Investig, 117, 1466, 10.1172/JCI32446

Patyar, 2010, Bacteria in cancer therapy: a novel experimental strategy, J Biomed Sci, 17, 10.1186/1423-0127-17-21

Xu, 2009, Combination of immunotherapy with anerobic bacteria for immunogene therapy of solid tumors, Gene Ther Mol Biol, 13, 36

Andersen, 2012, The specific targeting of immune regulation: T-cell responses against indoleamine 2,3-dioxygenase, Cancer Immunol Immunother, 61, 1289, 10.1007/s00262-012-1234-4

Byrne, 2011, Targeting regulatory T cells in cancer, Cancer Res, 71, 6915, 10.1158/0008-5472.CAN-11-1156

Rasku, 2008, Transient T cell depletion causes regression of melanoma metastases, J Transl Med, 6, 12, 10.1186/1479-5876-6-12

Marigo, 2008, Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells, Immunol Rev, 222, 162, 10.1111/j.1600-065X.2008.00602.x

Ostrand-Rosenberg, 2010, Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity, Cancer Immunol Immunother, 59, 1593, 10.1007/s00262-010-0855-8

Kim, 2012, Functional changes in myeloid-derived suppressor cells (MDSCs) during tumor growth: FKBP51 contributes to the regulation of the immunosuppressive function of MDSCs, J Immunol, 188, 4226, 10.4049/jimmunol.1103040

Gabrilovich, 2009, Myeloid-derived suppressor cells as regulators of the immune system, Nat Rev Immunol, 9, 162, 10.1038/nri2506

Melancon, 2010, Targeted imaging of tumor-associated M2 macrophages using a macromolecular contrast agent PG-Gd-NIR813, Biomaterials, 31, 6567, 10.1016/j.biomaterials.2010.05.001

Barten, 2001, Divergent and convergent evolution of NK-cell receptors, Trends Immunol, 22, 52, 10.1016/S1471-4906(00)01802-0

George, 1999, Tolerance and alloreactivity of the Ly49D subset of murine NK cells, J Immunol, 163, 1859, 10.4049/jimmunol.163.4.1859

Schmidt, 2012, Regulatory dendritic cells: there is more than just immune activation, Front Immunol, 3, 274, 10.3389/fimmu.2012.00274

Palucka, 2012, Cancer immunotherapy via dendritic cells, Nat Rev Cancer, 12, 265, 10.1038/nrc3258

Weber, 2007, Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events, Oncologist, 12, 864, 10.1634/theoncologist.12-7-864

Vinay, 2012, Immunotherapy of cancer with 4-1BB, Mol Cancer Ther, 11, 1062, 10.1158/1535-7163.MCT-11-0677

Topalian, 2012, Targeting the PD-1/B7-H1(PD-L1) pathway to activate antitumor immunity, Curr Opin Immunol, 24, 207, 10.1016/j.coi.2011.12.009

Kim, 2007, Expression of AITR and AITR ligand in breast cancer patients, Oncol Rep, 18, 1189

Shashidharamurthy, 2012, Immunotherapeutic strategies for cancer treatment: a novel protein transfer approach for cancer vaccine development, Med Res Rev, 32, 1197, 10.1002/med.20237

Rosenberg, 1999, A new era for cancer immunotherapy based on the genes that encode cancer antigens, Immunity, 10, 281, 10.1016/S1074-7613(00)80028-X

Van den Eynde, 1997, T cell defined tumor antigens, Curr Opin Immunol, 9, 684, 10.1016/S0952-7915(97)80050-7

Chen, 1997, A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening, Proc Nat Acad Sci USA, 94, 1914, 10.1073/pnas.94.5.1914

Ikeda, 1997, Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor, Immunity, 6, 199, 10.1016/S1074-7613(00)80426-4

Liu, 2004, Genetic and epigenetic modulation of telomerase activity in development and disease, Gene, 340, 1, 10.1016/j.gene.2004.06.011

Gu, 2000, Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers, Cancer Res, 60, 5359

Koga, 2000, A novel telomerase-specific gene therapy: gene transfer of caspase-8 utilizing the human telomerase catalytic subunit gene promoter, Hum Gene Ther, 11, 1397, 10.1089/10430340050057477

Oji, 1999, Expression of the Wilms’ tumor gene WT1 in solid tumors and its involvement in tumor cell growth, Jpn J Cancer Res, 90, 194, 10.1111/j.1349-7006.1999.tb00733.x

Oka, 2000, Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms’ tumor gene (WT1) product, Immunogenetics, 51, 99, 10.1007/s002510050018

Oka, 2006, Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancers, Curr Med Chem, 13, 2345, 10.2174/092986706777935104

Wolchok, 2012, How recent advances in immune therapy are changing the standard care for patients with metastatic melanoma, Ann Oncol, 23, 10.1093/annonc/mds258

Hodi, 2010, Improved survival with ipilimumab in patients with metastatic melanoma, N Engl J Med, 363, 711, 10.1056/NEJMoa1003466

Drake, 2012, Current status of immunological approaches for the treatment of prostate cancer, Curr Opin Urol, 22, 197, 10.1097/MOU.0b013e3283519ad5

Lynch, 2012, Ipilimumab in combination with Paciltaxel and Carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blinded, multicenter phase II study, J Clin Oncol, 30, 2046, 10.1200/JCO.2011.38.4032

Yang, 2007, Ipilimumab (anti-CTLA-4 antibody) causes regression of metastatic renal cells cancer as dissociated with enteritis and hypophysitis, J Immunother, 30, 825, 10.1097/CJI.0b013e318156e47e

Topalian, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Engl J Med, 366, 2443, 10.1056/NEJMoa1200690

Melero, 2013, Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination, Clin Cancer Res, 19, 997, 10.1158/1078-0432.CCR-12-2214

Jing, 2011, Depletion of CD25+ T cells from hematopoietic stem cell grafts increases posttransplantation vaccine-induced immunity to neuroblastoma, Blood, 117, 6952, 10.1182/blood-2010-12-326108

Nefedova, 2004, Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer, J Immunol, 172, 464, 10.4049/jimmunol.172.1.464

Wang, 2012, STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers, Int J Oncol, 41, 1181, 10.3892/ijo.2012.1568

Stagg, 2010, Extracellular adenosine triphosphatase and adenosine in cancer, Oncogene, 29, 5346, 10.1038/onc.2010.292

Beavis, 2013, Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors, Proc Natl Acad Sci USA, 110, 14711, 10.1073/pnas.1308209110

Allard, 2013, Targeting CD73 enhances the anti-tumor activity of anti-PD-1 and anti-CTLA-4 mAbs, Clin Can Res, 19, 5626, 10.1158/1078-0432.CCR-13-0545

Beavis, 2012, CD73: a potent suppressor of antitumor immune responses, Trends Immunol, 33, 231, 10.1016/j.it.2012.02.009

Stagg, 2010, Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis, Proc Natl Acad Sci USA, 107, 1547, 10.1073/pnas.0908801107

Stagg, 2011, CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis, Cancer Res, 71, 2892, 10.1158/0008-5472.CAN-10-4246

Stagg, 2011, CD73-deficient mice are resistant to carcinogenesis, Cancer Res, 71, 2892, 10.1158/0008-5472.CAN-10-4246

Ohta, 2006, A2A adenosine receptor protects tumors from anti-tumor T cells, Proc Natl Acad Sci USA, 103, 13132, 10.1073/pnas.0605251103

Gulley, 2013, Immune impact induced by PROSTVAC (PSA-TRICOM) a therapeutic vaccine for prostate cancer, Cancer Immunol Res, 2, 133, 10.1158/2326-6066.CIR-13-0108

Parmiani, 2002, Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?, J Natl Can Inst, 94, 805, 10.1093/jnci/94.11.805

Rivoltini, 1995, Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1, J Immunol, 154, 2257, 10.4049/jimmunol.154.5.2257

Cormier, 1997, Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A, Cancer J Sci Am, 3, 37

Salgaller, 1995, Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides, Cancer Res, 55, 4972

Marchand, 1999, Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1, Int J Cancer, 80, 219, 10.1002/(SICI)1097-0215(19990118)80:2<219::AID-IJC10>3.0.CO;2-S

Weber, 1999, A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma, J Immunother, 22, 431, 10.1097/00002371-199909000-00007

Rice, 2008, DNA vaccines: precision tools for activating effective immunity against cancer, Nat Rev Cancer, 8, 108, 10.1038/nrc2326

Lin, 2011, DNA vaccines: an historical perspective and view to the future, Immunol Rev, 239, 62, 10.1111/j.1600-065X.2010.00980.x

Chiarella, 2013, Electroporation in DNA vaccination protocols against cancer, Curr Drug Metab, 14, 291, 10.2174/1389200211314030004

Mir, 1999, High-efficiency gene transfer into skeletal muscle mediated by electric pulses, Proc Natl Acad Sci USA, 96, 4262, 10.1073/pnas.96.8.4262

Chiarella, 2008, Electroporation of skeletal muscle induces danger signal release and antigen-presenting cell recruitment independently of DNA vaccine administration, Expert Opin Biol Ther, 8, 1645, 10.1517/14712598.8.11.1645

Lichtor, 2005, Intratumoral injection of IL-secreting syngeneic/allogeneic fibroblasts transfected with DNA from breast cancer cells prolongs the survival of mice with intracerebral breast cancer, Cancer Gene Ther, 12, 708, 10.1038/sj.cgt.7700832

Lichtor, 2008, Enhanced immunity to intracerebral breast cancer in mice immunized with a cDNA-based vaccine enriched for immunotherapeutic cells, J Immunother, 31, 18, 10.1097/CJI.0b013e318157c64e

Nestle, 2000, Dendritic cell vaccination for cancer therapy, Oncogene, 19, 6673, 10.1038/sj.onc.1204095

Walter, 2012, Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival, Nat Med, 1254, 10.1038/nm.2883

Lutsiak, 2005, Inhibition of CD(+)CD25+ T regulatory cell function implicated in enhanced immune response by low-dose cycloohosphamide, Blood, 105, 2862, 10.1182/blood-2004-06-2410

Palucka, 2013, Dendritic-cell-based therapeutic cancer vaccines, Immunity, 39, 38, 10.1016/j.immuni.2013.07.004

Kantoff, 2010, Sipuleuciel-T immunotherapy for castration-resistant prostate cancer, N Engl J Med, 363, 411, 10.1056/NEJMoa1001294

Russo, 2010, Phytochemicals in cancer prevention and therapy: truth or dare?, Toxins, 2, 517, 10.3390/toxins2040517

Middleton, 1992, Effects of flavonoids on immune and inflammatory cell functions, Biochem Pharmacol, 43, 1167, 10.1016/0006-2952(92)90489-6

Calder, 2007, Immunomodulation by omega-3 fatty acids, Prostaglandins Leukot Essent Fatty Acids, 77, 327, 10.1016/j.plefa.2007.10.015

Dardenne, 2002, Zinc and immune function, Eur J Clin Nutr, 56, 520, 10.1038/sj.ejcn.1601479

Calder, 2002, The immune system: a target for functional foods?, Br J Nutr, 88, S165, 10.1079/BJN2002682

Hughes, 2001, Dietary carotenoids and human immune function, Nutrition, 10, 823, 10.1016/S0899-9007(01)00638-4

Kodama, 2003, Effect of Maitake (Grifola frondosa) D-fraction on the activation of NK cells in cancer patients, J Med Food, 6, 371, 10.1089/109662003772519949

Cole, 2007, Folic acid for the prevention of colorectal adenomas: a randomized clinical trial, JAMA, 6, 2351, 10.1001/jama.297.21.2351

Rock, 2007, Multivitamin-multimineral supplements: who uses them?, Am J Clin Nutr, 85, 2775, 10.1093/ajcn/85.1.277S

Kim, 2012, Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells, Br J Haematol, 158, 336, 10.1111/j.1365-2141.2012.09154.x

Singh, 2014, Natural killer T cell anergy, co-stimulatory molecules and immunotherapeutic interventions, Hum Immunol, 75, 250, 10.1016/j.humimm.2013.12.004

Ito, 2013, Helicobacter pylori cholesteryl α-glucosides contribute to its pathogenicity and immune response by natural killer T cells, PLOS ONE, 8, e78191, 10.1371/journal.pone.0078191

Jameson, 2003, T-cell effector mechanisms: gammadelta and CD1d-restricted subsets, Curr Opin Immunol, 15, 349, 10.1016/S0952-7915(03)00045-1

Cheng, 2014, SOCS1 hypermethylation mediated by DNMT1 is associated with lipopolysaccharide-induced inflammatory cytokines in macrophages, Toxicol Lett, 225, 488, 10.1016/j.toxlet.2013.12.023

Strauss, 2007, The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck, Clin Cancer Res, 13, 6301, 10.1158/1078-0432.CCR-07-1403

Stewart, 2013, Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation, J Clin Investig, 123, 4859, 10.1172/JCI65180

Whiteside, 2012, Induced and natural regulatory T cells in human cancer, Expert Opin Biol Ther, 12, 1383, 10.1517/14712598.2012.707184

Jia, 2012, Reduction of inflammatory hyperplasia in the intestine in colon cancer-prone mice by water-extract of Cistanche deserticola, Phytother Res, 26, 812, 10.1002/ptr.3637

Elkabets, 2010, IL-1β regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function, Eur J Immunol, 40, 3347, 10.1002/eji.201041037

Albulescu, 2013, Cytokine patterns in brain tumour progression, Mediat Inflamm, 2013, 979748, 10.1155/2013/979748

Day, 2013, Linking inflammation to tumorigenesis in a mouse model of high-fat-diet-enhanced colon cancer, Cytokine, 64, 454, 10.1016/j.cyto.2013.04.031

Fowler, 2012, Mycobacteria activate γδ T-cell anti-tumour responses via cytokines from type 1 myeloid dendritic cells: a mechanism of action for cancer immunotherapy, Cancer Immunol Immunother, 61, 535, 10.1007/s00262-011-1121-4

Fu, 2013, The crosstalk: tumor-infiltrating lymphocytes rich in regulatory T cells suppressed cancer-associated fibroblasts, Acta Oncol, 52, 1760, 10.3109/0284186X.2012.760847

Pahl, 2012, Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma, Clin Cancer Res, 18, 432, 10.1158/1078-0432.CCR-11-2277

Martinet, 2013, Drug-induced macrophage autophagy in atherosclerosis: for better or worse?, Basic Res Cardiol, 108, 321, 10.1007/s00395-012-0321-1

Li, 2014, Increased apoptosis induction in CD4+CD25+ Foxp3+ T cells contributes to enhanced disease activity in patients with rheumatoid arthritis through Il-10 regulation, Eur Rev Med Pharmacol Sci, 18, 78

Kawabe, 2012, IL-12 inhibits glucocorticoid-induced T cell apoptosis by inducing GMEB1 and activating PI3K/Akt pathway, Immunobiology, 217, 118, 10.1016/j.imbio.2011.07.018

Iannello, 2013, p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells, J Exp Med, 210, 2057, 10.1084/jem.20130783

Yao, 1999, Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12, Blood, 93, 1612, 10.1182/blood.V93.5.1612

Naldini, 2003, Regulation of angiogenesis by Th1- and Th2-type cytokines, Curr Pharm Des, 9, 511, 10.2174/1381612033391423

Larsen, 2012, Differential effects of Th1 versus Th2 cytokines in combination with hypoxia on HIFs and angiogenesis in RA, Arthritis Res Ther, 14, R180, 10.1186/ar3934

Rankin, 2003, An essential role of Th1 responses and interferon gamma in infection-mediated suppression of neoplastic growth, Cancer Biol Ther, 2, 687, 10.4161/cbt.2.6.557

Caccamo, 2010, Gammadelta T cell modulation in anticancer treatment, Curr Cancer Drug Targets, 10, 27, 10.2174/156800910790980188

Meraviglia, 2010, In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients, Clin Exp Immunol, 161, 290, 10.1111/j.1365-2249.2010.04167.x

Gomes, 2010, Targeting γδ T lymphocytes for cancer immunotherapy: from novel mechanistic insight to clinical application, Cancer Res, 70, 10024, 10.1158/0008-5472.CAN-10-3236

Wakita, 2010, Tumor-infiltrating IL-17-producing gammadelta T cells support the progression of tumor by promoting angiogenesis, Eur J Immunol, 40, 1927, 10.1002/eji.200940157

Pakala, 2002, Induction of endothelial cell proliferation by angiogenic factors released by activated monocytes, Cardiovasc Radiat Med, 3, 95, 10.1016/S1522-1865(02)00159-2

Facciabene, 2011, Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells, Nature, 475, 226, 10.1038/nature10169

Voest, 1995, Inhibition of angiogenesis in vivo by interleukin 12, J Natl Cancer Inst, 87, 581, 10.1093/jnci/87.8.581

Budhu, 2006, Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment, Cancer Cell, 10, 99, 10.1016/j.ccr.2006.06.016

Ferrarini, 2002, Human gammadelta T cells: a nonredundant system in the immune-surveillance against cancer, Trends Immunol, 23, 14, 10.1016/S1471-4906(01)02110-X

Pollard, 2004, Tumour-educated macrophages promote tumour progression and metastasis, Nat Rev Cancer, 4, 71, 10.1038/nrc1256

DeNardo, 2009, CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages, Cancer Cell, 16, 91, 10.1016/j.ccr.2009.06.018

Smyth, 2001, Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis, J Exp Med, 193, 661, 10.1084/jem.193.6.661

Shen, 2013, Interleukin-12 prevents colorectal cancer liver metastases in mice, OncoTargets Ther, 6, 523

Thakur, 2012, A Th1 cytokine-enriched microenvironment enhances tumor killing by activated T cells armed with bispecific antibodies and inhibits the development of myeloid-derived suppressor cells, Cancer Immunol Immunother, 61, 497, 10.1007/s00262-011-1116-1

Ye, 2013, Specific recruitment of γδ regulatory T cells in human breast cancer, Cancer Res, 73, 6137, 10.1158/0008-5472.CAN-13-0348

Lamagna, 2006, Dual role of macrophages in tumor growth and angiogenesis, J Leukoc Biol, 80, 705, 10.1189/jlb.1105656

Schoppmann, 2002, Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis, Am J Pathol, 161, 947, 10.1016/S0002-9440(10)64255-1

Tsung, 2002, Macrophages as effector cells in interleukin 12-induced T cell-dependent tumor rejection, Cancer Res, 62, 5069

Wu, 2013, Immune microenvironment profiles of tumor immune equilibrium and immune escape states of mouse sarcoma, Cancer Lett, 340, 124, 10.1016/j.canlet.2013.07.038

Hayakawa, 2011, Early activation and interferon-γ production of tumor-infiltrating mature CD27 high natural killer cells, Cancer Sci, 102, 1967, 10.1111/j.1349-7006.2011.02042.x

Kerkar, 2011, IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors, J Clin Investig, 121, 4746, 10.1172/JCI58814

Schepetkin, 2006, Botanical polysaccharides: macrophage immunomodulation and therapeutic potential, Int Immunopharmacol, 6, 317, 10.1016/j.intimp.2005.10.005

Jeff, 2013, Purification and in vitro anti-proliferative effect of novel neutral polysaccharides from Lentinus edodes, Int J Biol Macromol, 52, 99, 10.1016/j.ijbiomac.2012.10.007

Zhao, 2013, Effect of lentinan combined with docetaxel and cisplatin on the proliferation and apoptosis of BGC823 cells, Tumour Biol, 34, 1531, 10.1007/s13277-013-0680-8

Wakshlag, 2010, Evaluation of the protective effects of all-trans-astaxanthin on canine osteosarcoma cell lines, Am J Vet Res, 71, 89, 10.2460/ajvr.71.1.89

Yasui, 2011, Dietary astaxanthin inhibits colitis and colitis-associated colon carcinogenesis in mice via modulation of the inflammatory cytokines, Chem Biol Interact, 193, 79, 10.1016/j.cbi.2011.05.006

Tanaka, 1995, Suppression of azoxymethane-induced rat colon carcinogenesis by dietary administration of naturally occurring xanthophylls astaxanthin and canthaxanthin during the postinitiation phase, Carcinogenesis, 16, 2957, 10.1093/carcin/16.12.2957

Sliva, 2012, Mushroom Ganoderma lucidum prevents colitis-associated carcinogenesis in mice, PLoS ONE, 7, e47873, 10.1371/journal.pone.0047873

Joseph, 2011, Antitumor and anti-inflammatory activities of polysaccharides isolated from Ganoderma lucidum, Acta Pharm, 61, 335, 10.2478/v10007-011-0030-6

Yang, 2013, Antitumor and immunomodulatory activity of Astragalus membranaceus polysaccharides in H22 tumor-bearing mice, Int J Biol Macromol, 62, 287, 10.1016/j.ijbiomac.2013.09.016

Nishitani, 2013, Intestinal anti-inflammatory activity of lentinan: influence on IL-8 and TNFR1 expression in intestinal epithelial cells, PLOS ONE, 8, e62441, 10.1371/journal.pone.0062441

Bisen, 2010, Lentinus edodes: a macrofungus with pharmacological activities, Curr Med Chem, 17, 2419, 10.2174/092986710791698495

Speranza, 2012, Astaxanthin treatment reduced oxidative induced pro-inflammatory cytokines secretion in U937: SHP-1 as a novel biological target, Mar Drugs, 10, 890, 10.3390/md10040890

Hsieh, 2011, Suppression of proliferation and oxidative stress by extracts of Ganoderma lucidum in the ovarian cancer cell line OVCAR-3, Int J Mol Med, 28, 1065

Jiang, 2004, Ganoderma lucidum suppresses growth of breast cancer cells through the inhibition of Akt/NF-kappaB signaling, Nutr Cancer, 49, 209, 10.1207/s15327914nc4902_13

Hsieh, 2006, Induction of cell cycle changes and modulation of apoptogenic/anti-apoptotic and extracellular signaling regulatory protein expression by water extracts of I’m-Yunity (PSP), BMC Complement Altern Med, 6, 30, 10.1186/1472-6882-6-30

Auyeung, 2009, Astragalus saponins induce apoptosis via an ERK-independent NF-kappaB signaling pathway in the human hepatocellular HepG2 cell line, Int J Mol Med, 23, 189

Fang, 2006, Inhibition of growth and induction of apoptosis in human cancer cell lines by an ethyl acetate fraction from shiitake mushrooms, J Altern Complement Med, 12, 125, 10.1089/acm.2006.12.125

Palozza, 2009, Growth-inhibitory effects of the astaxanthin-rich alga Haematococcus pluvialis in human colon cancer cells, Cancer Lett, 283, 108, 10.1016/j.canlet.2009.03.031

Gao, 2005, Antitumor activity and underlying mechanisms of ganopoly, the refined polysaccharides extracted from Ganoderma lucidum, in mice, Immunol Investig, 34, 171, 10.1081/IMM-55813

Wang, 2013, Astragalus saponins affect proliferation, invasion and apoptosis of gastric cancer BGC-823 cells, Diagn Pathol, 8, 179, 10.1186/1746-1596-8-179

Wang, 2013, Structure and inducing tumor cell apoptosis activity of polysaccharides isolated from Lentinus edodes, J Agric Food Chem, 61, 9849, 10.1021/jf403291w

Kavitha, 2013, Astaxanthin inhibits NF-κB and Wnt/β-catenin signaling pathways via inactivation of Erk/MAPK and PI3K/Akt to induce intrinsic apoptosis in a hamster model of oral cancer, Biochim Biophys Acta, 1830, 4433, 10.1016/j.bbagen.2013.05.032

Wesolowska, 2010, Stilbenes as multidrug resistance modulators and apoptosis inducers in human adenocarcinoma cells, Anticancer Res, 30, 4587

Yuen, 2008, Telomerase-associated apoptotic events by mushroom ganoderma lucidum on premalignant human urothelial cells, Nutr Cancer, 60, 109, 10.1080/01635580701525869

Gao, 2004, Ganoderma lucidum polysaccharide fractions accelerate healing of acetic acid-induced ulcers in rats, J Med Food, 7, 417, 10.1089/jmf.2004.7.417

Cao, 2004, Antitumor and anti-angiogenic activity of Ganoderma lucidum polysaccharides peptide, Acta Pharmacol Sin, 25, 833

Zhang, 2011, Astragalus membranaceus extract promotes neovascularisation by VEGF pathway in rat model of ischemic injury, Pharmazie, 66, 144

Sano, 2002, Antitumor effects induced by the combination of TNP-470 as an angiogenesis inhibitor and lentinan as a biological response modifier in a rabbit spontaneous liver metastasis model, Surg Today, 32, 503, 10.1007/s005950200085

Kim, 2013, A novel resveratrol analogue, HS-1793, inhibits hypoxia-induced HIF-1α and VEGF expression, and migration in human prostate cancer cells, Int J Oncol, 43, 1915, 10.3892/ijo.2013.2116

Sliva, 2002, Ganoderma lucidum suppresses motility of highly invasive breast and prostate cancer cells, Biochem Biophys Res Commun, 298, 603, 10.1016/S0006-291X(02)02496-8

Liu, 2010, Compound Astragalus and Salvia miltiorrhiza extract inhibits cell invasion by modulating transforming growth factor-beta/Smad in HepG2 cell, J Gastroenterol Hepatol, 25, 420, 10.1111/j.1440-1746.2009.05981.x

Ren, 2012, Antitumor activity of mushroom polysaccharides: a review, Food Funct, 3, 1118, 10.1039/c2fo10279j

Ogasawara, 2007, Differential effects of antioxidants on the in vitro invasion, growth and lung metastasis of murine colon cancer cells, Biol Pharm Bull, 30, 200, 10.1248/bpb.30.200

Polonini, 2013, Photoprotective activity of resveratrol analogues, Bioorg Med Chem, 21, 964, 10.1016/j.bmc.2012.11.052

Mikstacka, 2010, Chemopreventive and chemotherapeutic effect of trans-resveratrol and its analogues in cancer, Pol Merkur Lekarski, 28, 496

Lu, 2014, Antagonism by Ganoderma lucidum polysaccharides against the suppression by culture supernatants of B16F10 melanoma cells on macrophage, Phytother Res, 28, 200, 10.1002/ptr.4980

Ono, 2012, Direct inhibition of the transforming growth factor-β pathway by protein-bound polysaccharide through inactivation of Smad2 signaling, Cancer Sci, 103, 317, 10.1111/j.1349-7006.2011.02133.x

Li, 2012, Inhibiting effect of Astragalus polysaccharides on the functions of CD4+CD25 highTreg cells in the tumor microenvironment of human hepatocellular carcinoma, Chin Med J (Engl), 125, 786

Zong, 2012, Anticancer polysaccharides from natural resources: a review of recent research, Carbohydr Polym, 904, 1395, 10.1016/j.carbpol.2012.07.026

Nagendraprabhu, 2011, Astaxanthin inhibits tumor invasion by decreasing extracellular matrix production and induces apoptosis in experimental rat colon carcinogenesis by modulating the expressions of ERK-2, NFkB and COX-2, Investig New Drugs, 29, 207, 10.1007/s10637-009-9342-5

Choi, 2012, Resveratrol analogue HS-1793 induces the modulation of tumor-derived T cells, Exp Ther Med, 3, 592, 10.3892/etm.2012.472

Goodnow, 2005, Cellular and genetic mechanisms of self tolerance and autoimmunity, Nature, 435, 590, 10.1038/nature03724

Rosenberg, 1988, Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report, N Engl J Med, 319, 1676, 10.1056/NEJM198812223192527

Rosenberg, 1994, Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2, J Natl Cancer Inst, 86, 1159, 10.1093/jnci/86.15.1159

Dudley, 2002, Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes, Science, 298, 850, 10.1126/science.1076514

Rosenberg, 2008, Adoptive cell transfer: a clinical path to effective cancer immunotherapy, Nat Rev Cancer, 8, 299, 10.1038/nrc2355

Schietinger, 2012, Rescued tolerant CD8 T cells are preprogrammed to reestablish the tolerant state, Science, 335, 723, 10.1126/science.1214277

King, 2004, Homeostatic expansion of T cells during immune insufficiency generates autoimmunity, Cell, 117, 265, 10.1016/S0092-8674(04)00335-6

Lee, 1999, Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients, Nat Med, 5, 677, 10.1038/9525

Nagorsen, 2003, Natural T cell immunity against cancer, Clin Cancer Res, 9, 4296

Rosenberg, 2011, Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy, Clin Cancer Res, 17, 4550, 10.1158/1078-0432.CCR-11-0116

Rosenberg, 2003, Recombinant fowlfox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune response in patients with metastatic melanoma, Clin Cancer Res, 9, 2973

Choi, 2014, 4-1BB-based isolation and expansion of CD8+ T cells specific for self and non-self tumor antigens for adoptive T cell therapy, J Immunother, 37, 225, 10.1097/CJI.0000000000000027

Kalos, 2012, Muscle CARs and TcRs: turbo-charged technologies for the (T cell) masses, Cancer Immunol Immunother, 61, 127, 10.1007/s00262-011-1173-5